These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9354694)

  • 41. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT.
    Radich J; Ladne P; Gooley T
    Biol Blood Marrow Transplant; 1995 Nov; 1(1):24-31. PubMed ID: 9118286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
    Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
    Genuardi E; Klous P; Mantoan B; Drandi D; Ferrante M; Cavallo F; Alessandria B; Dogliotti I; Grimaldi D; Ragaini S; Clerico M; Lo Schirico M; Saraci E; Yilmaz M; Zaccaria GM; Cortelazzo S; Vitolo U; Luminari S; Federico M; Boccadoro M; van Min M; Splinter E; Ladetto M; Ferrero S
    Hematol Oncol; 2021 Aug; 39(3):293-303. PubMed ID: 33742718
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
    Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
    Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders.
    Drandi D; Ferrero S; Ladetto M
    Methods Mol Biol; 2018; 1768():229-256. PubMed ID: 29717447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.
    Ratanatharathorn V; Uberti J; Karanes C; Abella E; Lum LG; Momin F; Cummings G; Sensenbrenner LL
    Blood; 1994 Aug; 84(4):1050-5. PubMed ID: 8049425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.
    Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM
    J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).
    Nagler A; Condiotti R; Rabinowitz R; Schlesinger M; Nguyen M; Terstappen LW
    Med Oncol; 1999 Sep; 16(3):177-87. PubMed ID: 10523797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy].
    Zhou A; Shi Y; Feng F; Lu S; He X; Han X
    Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):467-70. PubMed ID: 12485501
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
    Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
    Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging.
    Uckun FM; Kersey JH; Vallera DA; Ledbetter JA; Weisdorf D; Myers DE; Haake R; Ramsay NK
    Blood; 1990 Nov; 76(9):1723-33. PubMed ID: 2224122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
    Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
    Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
    Miyamura K; Tanimoto M; Morishima Y; Horibe K; Yamamoto K; Akatsuka M; Kodera Y; Kojima S; Matsuyama K; Hirabayashi N
    Blood; 1992 Mar; 79(5):1366-70. PubMed ID: 1371420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma.
    Mitterbauer M; Neumeister P; Kalhs P; Brugger S; Fischer G; Dieckmann K; Hoecker P; Hinterberger W; Linkesch W; Simonitsch I; Jaeger U; Lechner K; Mannhalter C; Mitterbauer G; Greinix HT
    Leukemia; 2001 Apr; 15(4):635-41. PubMed ID: 11368367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Assessment of minimal residual disease in adult patients with B-lineage acute lymphoblastic leukemia using rearranged immunoglobulin loci detection].
    Yao L; Chen ZX; Cen JN; Liu H; He J; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):433-7. PubMed ID: 21122394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Pott C; Schrader C; Brüggemann M; Ritgen M; Harder L; Raff T; Tiemann M; Dreger P; Kneba M
    Eur J Haematol; 2005 Apr; 74(4):353-8. PubMed ID: 15777349
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
    Friedberg JW; Neuberg D; Gribben JG; Mauch P; Anderson KC; Soiffer RJ; Takvorian T; Fisher DC; Schlossman R; Jallow H; Kuhlman C; Ritz J; Freedman AS
    Biol Blood Marrow Transplant; 1999; 5(4):262-8. PubMed ID: 10465106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.